Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.

Yahoo Finance Published Updated Economy
Sign in to save

Why it matters

Moderna's stock rises after the FDA announces it will review the company's seasonal flu vaccine candidate, a reversal from its earlier rejection.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 90% confidence.

Evidence trail

Evidence
Source Yahoo Finance
Claim Moderna Stock Rises. FDA Will Review Its Seasonal Flu Vaccine After All.
AI inference Bullish · 90%
Generated 2026-02-18 17:12

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
47218

Original source

The Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.

Read the full article on Yahoo Finance

Original article published by Yahoo Finance on February 18, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage